Sessa Capital’s Ascendis Pharma A/S ASND Stock Holding History

Sessa Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-58,500	Closed	-$7.14M	–	40
2022 Q4	$7.14M	Hold	58,500	–	–	0.44%	22
2022 Q3	$6.04M	Hold	58,500	–	–	0.43%	23
2022 Q2	$5.44M	Hold	58,500	–	–	0.3%	24
2022 Q1	$6.87M	Buy	+58,500	New	+$6.78M	0.33%	29

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sessa Capital's ASND Position: Q1 2023 in Review

Sessa Capital sold out of Ascendis Pharma A/S (ASND) in Q1 2023, closing a stake of 58,500 shares — an estimated $7.14M sold.

Sessa Capital first reported a position in ASND in Q1 2022 and held it in 4 quarters. The position peaked at $7.14M in Q4 2022. 164 funds tracked by Wall St. Rank hold ASND as of Q1 2023.

Sessa Capital reported no remaining Ascendis Pharma A/S position as of Q1 2023 after selling out during the quarter.
Sessa Capital sold 58,500 Ascendis Pharma A/S shares in Q1 2023, an estimated $7.14M.
Sessa Capital first reported a position in Ascendis Pharma A/S in Q1 2022 and held it in 4 quarters.
Sessa Capital's Ascendis Pharma A/S position peaked at $7.14M in Q4 2022.
164 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2023.

Based on Sessa Capital's 13F filing for Q1 2023, filed 15 May 2023.